Publications

CHPA launched a new podcast – CHPA Chat – providing stories and insights from staff, industry leaders, academics, and healthcare providers about the trends and issues facing the consumer healthcare space.

We are delighted to share CHPA’s 2020 Annual Report and CHPA Educational Foundation' Annual Report, which provides highlights of the past year.

For its annual year-in-review series, Chain Drug Review featured CHPA's President & CEO, Scott Melville, who offered industry insights from last year and thoughts on the outlook for 2021.

Despite the challenges of COVID-19 in 2020, CHPA remained hard at work on behalf of its members.

What follows is a timeline for implementation of OTC monograph reform under HR 748, also known as the CARES Act.

CHPA, its educational foundation, and member companies are empowering consumers to practice responsible self-care, providing resources to help respond to this pandemic. We’re guided by these core principles.

CHPA continues to monitor state and local orders for healthcare-related workforce and logistics disruptions as they are announced.

Find detailed information about each section of the CARES Act, which was passed in 2020 in response to the COVID-19 pandemic.

CHPA continues to closely monitor the rapidly-evolving Coronavirus Disease 2019 (COVID-19) outbreak.

Acetaminophen was chosen for review by OEHHA in part because the Prop 65 regulation emphasizes chemicals with “widespread exposure.” The Carcinogen Identification Committee will review the information on acetaminophen and cancer to determine whether acetaminophen should be listed as a carcinogen under Proposition 65.

Scientific experts familiar with herbal products and their testing methods maintain that the DNA barcode test is not an appropriate method to determine what is in an herbal dietary supplement.